

CITATION REPORT

List of articles citing

Therapeutic drug monitoring of the newer antiepileptic drugs

DOI: 10.1097/00007691-200306000-00016
Therapeutic Drug Monitoring, 2003, 25, 347-63.

Source: <https://exaly.com/paper-pdf/36034242/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
269	Clinical pharmacokinetics of oxcarbazepine. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 1023-42	6.2	156
268	Associative somatodendritic interaction in layer V pyramidal neurons is not affected by the antiepileptic drug lamotrigine. 2004 , 20, 1688-93		11
267	Severe overdosage with the antiepileptic drug oxcarbazepine. <i>British Journal of Clinical Pharmacology</i> , 2004 , 58, 329-31	3.8	17
266	The activity of antiepileptic drugs as histone deacetylase inhibitors. <i>Epilepsia</i> , 2004 , 45, 737-44	6.4	162
265	Therapeutic drug monitoring of antiepileptic drugs. <i>Handbook of Analytical Separations</i> , 2004 , 5, 221-253.7		3
264	Clinical pharmacokinetics of levetiracetam. <i>Clinical Pharmacokinetics</i> , 2004 , 43, 707-24	6.2	287
263	Therapeutic drug monitoring of old and newer anti-epileptic drugs. 2004 , 42, 1228-55		116
262	Seizure disorders in pregnancy. 2004 , 31, 373-84, vii		7
261	Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. <i>Epilepsy and Behavior</i> , 2004 , 5, 866-72	3.2	54
260	Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD). <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 300-4	3.2	23
259	Long-term follow-up using a higher target range for lamotrigine monitoring. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 626-32	3.2	21
258	Can pharmacokinetic variability be controlled for the patient's benefit? The place of TDM for new AEDs. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 710-3	3.2	17
257	Lamotrigine in psychiatry: pharmacology and therapeutics. 2005 , 10, 224-32		10
256	Cost-effectiveness of therapeutic drug monitoring: a systematic review. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 10-7	3.2	145
255	How to assess phenytoin levels. 2005 , 35, 18-9		
254	Simultaneous determination of lamotrigine, phenobarbitone, carbamazepine and phenytoin in human serum by high-performance liquid chromatography. 2005 , 39, 181-6		66
253	High-performance thin-layer chromatographic determination of lamotrigine in serum. 2005 , 823, 152-7		21

252	Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase. 2005 , 63, 103-12	80
251	Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents. 2005 , 63, 17-25	89
250	Rapid Tandem Mass Spectrometric Method for Determination of Gabapentin in Human Plasma. 2005 , 61, 499-504	12
249	Effects of anticonvulsants on human p450c17 (17alpha-hydroxylase/17,20 lyase) and 3beta-hydroxysteroid dehydrogenase type 2. <i>Epilepsia</i> , 2005 , 46, 444-8	6.4 20
248	Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. 2005 , 69, 1501-8	41
247	Drug monitoring in combination therapy. 2005 , 392-402	
246	Pharmacokinetic Properties of New Antiepileptic Drugs. 2005 , 18, 444-460	8
245	Quantification of Vigabatrin in Human Plasma by Liquid ChromatographyElectrospray Tandem Mass Spectrometry. 2005 , 28, 395-406	6
244	Tiagabine overdose: a case of status epilepticus in a non-epileptic patient. 2005 , 43, 869-71	23
243	Quantitative determination of vigabatrin and gabapentin in human serum by gas chromatography-mass spectrometry. 2005 , 354, 147-51	43
242	Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy. 2005 , 27, 618-26	10
241	Recruitment rates and fear of phlebotomy in pediatric patients in a genetic study of epilepsy. <i>Epilepsy and Behavior</i> , 2005 , 6, 444-6	3.2 22
240	Biphasic actions of topiramate on monoamine exocytosis associated with both soluble N-ethylmaleimide-sensitive factor attachment protein receptors and Ca(2+)-induced Ca(2+)-releasing systems. 2005 , 134, 233-46	45
239	Lack of pharmacokinetic interactions between steady-state zonisamide and valproic acid in patients with epilepsy. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 517-23	6.2 22
238	Simulated fluctuations in plasma drug concentrations for patients receiving oxcarbazepine or carbamazepine extended-release capsules. 2005 , 25, 669-73	5
237	Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful?. 2006 , 20, 791-800	29
236	Pediatric case report of topiramate toxicity. 2006 , 44, 67-9	15
235	Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 351-63	6.2 93

234	Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 1061-75	6.2	162
233	Management of focal-onset seizures: an update on drug treatment. 2006 , 66, 1701-25		18
232	Anticonvulsant therapy in dogs and cats. 2006 , 36, 1107-27, vii		54
231	Determination of lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 603-7	3.2	43
230	Application of TDM, pharmacogenomics and biomarkers for neurological disease pharmacotherapy: focus on antiepileptic drugs. 2006 , 3, 139-149		4
229	Determination of gabapentin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry. 2006 , 20, 2127-32		37
228	Use of antiepileptic drugs in patients with kidney disease. 2006 , 19, 408-16		37
227	In situ metabolism of levetiracetam in blood of patients with epilepsy. <i>Epilepsia</i> , 2006 , 47, 1818-21	6.4	39
226	Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006 , 31, 211-21	2.2	21
225	The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. 2006 , 149, 250-60		56
224	Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy. 2006 , 69, 170-6		39
223	Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. 2006 , 80, 159-68		61
222	Therapeutic drug monitoring assay development to improve efficacy and safety. 2006 , 68, 60-3		6
221	Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. <i>European Journal of Clinical Pharmacology</i> , 2006 , 62, 737-42	2.8	9
220	Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. 2006 , 26, 627-33		14
219	Drug monitoring and toxicology: a procedure for the monitoring of oxcarbazepine metabolite by HPLC-UV. 2006 , 44, 45-8		16
218	Drug monitoring and toxicology: a procedure for the monitoring of levetiracetam and zonisamide by HPLC-UV. 2006 , 30, 27-30		38
217	Therapeutisches Drug Monitoring in der PÄdiatrie / Therapeutic drug management in pediatric patients. 2007 , 31, 24-37		

216	Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 576-83	3.2	49
215	Clinical use of antiepileptic drugs at a referral centre for epilepsy. 2007 , 16, 356-64		35
214	Effects of phenytoin and carbamazepine on calcium transport in Caco-2 cells. 2007 , 21, 855-62		21
213	Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. 2007 , 377, 1-13		120
212	High-affinity GABA uptake and GABA-metabolizing enzymes in pig forebrain white matter: a quantitative study. 2007 , 50, 365-70		8
211	Salivary Monitoring of Antiepileptic Drugs. 2007 , 20, 147-157		5
210	Assessment of antiepileptic drugs as substrates for canine P-glycoprotein. 2007 , 68, 1106-10		25
209	Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 209-19	6.2	81
208	The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 271-9	6.2	92
207	Population pharmacokinetics of levetiracetam in Japanese and Western adults. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 503-12	6.2	40
206	Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma. <i>Biomedical Chromatography</i> , 2007 , 21, 1127-34	1.7	29
205	Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules. 2007 , 76, 140-7		15
204	Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. <i>Epilepsia</i> , 2007 , 48, 1351-9	6.4	69
203	Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. <i>Epilepsia</i> , 2007 , 48, 1850-60	6.4	94
202	Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. <i>Epilepsia</i> , 2007 , 48, 2111-5	6.4	45
201	Generic products of antiepileptic drugs (AEDs): is it an issue?. <i>Epilepsia</i> , 2007 , 48, 1825-32	6.4	59
200	Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain. <i>Epilepsia</i> , 2007 , 48 Suppl 5, 19-26	6.4	87
199	Isocratic Reversed-Phase HPLC for Simultaneous Separation and Determination of Seven Antiepileptic Drugs and Two of their Active Metabolites in Human Plasma. 2007 , 65, 267-275		20

198	A Capillary GC Method Using Nitrogen Phosphorus Detection for Determination of Topiramate in Patients with Epilepsy. 2007 , 66, 363-367		11
197	Tiagabine does not attenuate alcohol-induced activation of the human reward system. 2007 , 191, 975-83		11
196	Preparation and characterization of a lamotrigine imprinted polymer and its application for drug assay in human serum. 2008 , 31, 3595-602		39
195	Determination of plasma topiramate concentration using LC-MS/MS for pharmacokinetic and bioequivalence studies in healthy Korean volunteers. <i>Biomedical Chromatography</i> , 2008 , 22, 822-9	1.7	16
194	An oxcarbazepine-related fatality with an overview of 26 oxcarbazepine postmortem cases. 2008 , 177, 248-51		9
193	Value of therapeutic drug monitoring in epilepsy. 2008 , 8, 929-39		37
192	Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. 2008 , 14, 120-42		94
191	Development of tolerance to levetiracetam in rats with chronic epilepsy. <i>Epilepsia</i> , 2008 , 49, 1151-9	6.4	35
190	Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i> , 2008 , 49, 1239-76	6.4	703
189	Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs. 2008 , 31, 544-53		24
188	Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2008 , 66, 396-404	3.8	72
187	The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs. 2008 , 176, 310-9		73
186	Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 333-41	6.2	41
185	Does oxcarbazepine warrant therapeutic drug monitoring? A critical review. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 767-78	6.2	16
184	Handbook of Drug Monitoring Methods. 2008 ,		8
183	Long-term levetiracetam treatment affects reproductive endocrine function in female Wistar rats. 2008 , 17, 203-9		27
182	Lamotrigine therapeutic thresholds. 2008 , 17, 391-5		27
181	A probable case of gabapentin-related reversible hearing loss in a patient with acute renal failure. 2008 , 30, 1681-4		10

180	Efficiency and safety of oxcarbazepine in mood disorders: a naturalistic study exploring the interest of plasma dosages. 2008 , 23, 409-12		5
179	The effect of anticonvulsant drugs on the fibrinolytic activity of tissue plasminogen activator. 2008 , 25, 107-10		4
178	Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. 2008 , 105, 3628-33		304
177	Clinical Laboratory Investigation and Psychiatry. 2008 ,		0
176	Drug monitoring and toxicology: a simple procedure for the monitoring of felbamate by HPLC-UV detection. 2008 , 32, 373-8		6
175	Introduction to Therapeutic Drug Monitoring. 2008 , 1-39		2
174	The effect of amitriptyline, gabapentin, and carbamazepine on morphine-induced hypercarbia in rabbits. 2008 , 107, 1216-22		9
173	High-speed simultaneous determination of nine antiepileptic drugs using liquid chromatography-mass spectrometry. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 347-56	3.2	78
172	Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 173-80	3.2	51
171	Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 483-9	3.2	37
170	Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release. 2008 , 4, 1035-46		30
169	Development and validation of a rapid column-switching high-performance liquid chromatographic method for the determination of Lamotrigine in human serum. 2009 , 47, 478-84		13
168	Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers. <i>Biomedical Chromatography</i> , 2009 , 23, 1227-41	1.7	11
167	Trends and changes in the clinical use of lamotrigine. 2009 , 18, 132-9		16
166	Acute oxcarbazepine overdose in an autistic boy. <i>British Journal of Clinical Pharmacology</i> , 2009 , 67, 579-81		7
165	Anticonvulsants in bipolar disorders: current research and practice and future directions. 2009 , 11 Suppl 2, 20-33		41
164	Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. <i>Epilepsia</i> , 2009 , 50, 1150-7	6.4	32
163	Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. <i>Epilepsia</i> , 2010 , 51, 941-50	6.4	40

162	Pharmacokinetics of levetiracetam XR 500mg tablets. 2009 , 84, 224-31		25
161	Levetiracetam accumulation in renal failure causing myoclonic encephalopathy with triphasic waves. 2009 , 18, 376-8		24
160	Epilepsia partialis continua responsive to intravenous levetiracetam. 2009 , 18, 716-8		9
159	The Maudsley Prescribing Guidelines. 2009 ,		110
158	Clinical pharmacology of levetiracetam for the treatment of epilepsy. 2009 , 2, 339-50		6
157	A novel HPLC method for quantification of 10 antiepileptic drugs or metabolites in serum/plasma using a monolithic column. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 102-6	3.2	35
156	[Therapeutic drug monitoring of vigabatrin]. 2010 , 65, 23-7		2
155	[Therapeutic drug monitoring of tiagabine]. 2010 , 65, 51-5		0
154	[Therapeutic drug monitoring of topiramate]. 2010 , 65, 17-22		2
153	Effect of the administration of tiagabine and gabapentin on rabbit electroencephalogram activity. 2006 , 58, 1367-72		
152	Simultaneous HPLC-F analysis of three recent antiepileptic drugs in human plasma. 2010 , 53, 62-7		28
151	Effect of carbamazepine and oxcarbazepine on wild-type and mutant neuronal nicotinic acetylcholine receptors linked to nocturnal frontal lobe epilepsy. 2010 , 643, 13-20		20
150	Inhibitory effects of levetiracetam on absence seizures in a novel absence-like epilepsy animal model, Groggy rat. 2010 , 1359, 298-303		6
149	Region-specific changes in gene expression in rat brain after chronic treatment with levetiracetam or phenytoin. <i>Epilepsia</i> , 2010 , 51, 1714-20	6.4	10
148	Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications. 2010 , 3, 1909-1935		26
147	Pharmacology of antiepileptic drugs in clinical practice. 2010 , 16, 353-7		11
146	Acute modulation of calcium currents and synaptic transmission by gabapentinoids. 2010 , 4, 490-6		33
145	Therapeutic drug monitoring of topiramate by liquid chromatography-tandem mass spectrometry. 2010 , 411, 729-34		20

144	Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. 2010 , 123, 367-73			50
143	Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications. 2010 , 3, 1909-1935			85
142	A Clinical Guide to Epileptic Syndromes and their Treatment. 2010 ,			71
141	Pharmacokinetic Monitoring of Antiepileptic Drugs. 2011 , 35, 326-339			2
140	Neuroprotective effect of levetiracetam on hippocampal sclerosis-like change in spontaneously epileptic rats. 2011 , 86, 36-41			11
139	Modulation of abnormal synaptic transmission in hippocampal CA3 neurons of spontaneously epileptic rats (SERs) by levetiracetam. 2011 , 86, 334-9			10
138	Therapeutic Drug Monitoring of Antiepileptic Medications. 2011 ,			
137	Modern methods for analysis of antiepileptic drugs in the biological fluids for pharmacokinetics, bioequivalence and therapeutic drug monitoring. 2011 , 15, 67-81			23
136	Performance characteristics of a new levetiracetam immunoassay and method comparison with a high-performance liquid chromatography method. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 124-7	3.2		12
135	Simultaneous quantification of levetiracetam and gabapentin in plasma by ultra-pressure liquid chromatography coupled with tandem mass spectrometry detection. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 209-13	3.2		18
134	Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. 2011 , 31, 934-41			40
133	Pharmacokinetic monitoring of antiepileptic drugs. 2011 , 35, 326-39			13
132	Effects of antiepileptic drugs on glutamate release from rat and human neocortical synaptosomes. 2011 , 383, 531-42			29
131	Effects of antiepileptic drugs on GABA release from rat and human neocortical synaptosomes. 2011 , 384, 47-57			29
130	Development and validation of a reference measurement procedure for certification of phenytoin, phenobarbital, lamotrigine, and topiramate in human serum using isotope-dilution liquid chromatography/tandem mass spectrometry. 2011 , 401, 1915-22			21
129	Quantitative dynamic nuclear polarization-NMR on blood plasma for assays of drug metabolism. 2011 , 24, 96-103			35
128	A rapid and simple assay for lamotrigine in serum/plasma by HPLC, and comparison with an immunoassay. <i>Biomedical Chromatography</i> , 2011 , 25, 775-8	1.7		13
127	Pregabalin modulation of neurotransmitter release is mediated by change in intrinsic activation/inactivation properties of $Ca_v2.1$ calcium channels. 2011 , 336, 973-82			23

126	An initial experience with therapeutic drug monitoring of levetiracetam as reported from a pediatric clinical setting in India. 2012 , 60, 146-9		9
125	Neurology and Pregnancy. 2012 ,		
124	Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 440-5	3.2	65
123	Therapeutic Drug Monitoring of Classical and Newer Anticonvulsants. 2012 , 243-267		3
122	Disposition of drugs in pregnancy: anti-epileptic drugs. 2012 , 27-33		
121	Non-Derivatization Method for the Determination of Gabapentin in Pharmaceutical Formulations, Rat Serum and Rat Urine using High Performance Liquid Chromatography Coupled with Charged Aerosol Detection. 2012 , 8, 159-167		9
120	Assessment of the effects of adjunctive gabapentin on postoperative pain after intervertebral disc surgery in dogs. 2012 , 39, 636-46		42
119	Central Nervous System Drugs. 2012 , 301-329		1
118	Recurrent seizures in a levetiracetam-treated patient after subarachnoid hemorrhage: a matter of enhanced renal function?. <i>Epilepsy and Behavior</i> , 2012 , 23, 394-5	3.2	6
117	Performance characteristics and patient comparison of the ARK Diagnostics levetiracetam immunoassay with an ultra-high performance liquid chromatography with tandem mass spectrometry detection method. 2012 , 413, 529-31		11
116	Introduction to Epilepsy. 353-357		
115	Introduction to Epilepsy. 358-366		
114	Second-generation antiepileptic drugs and pregnancy: a guide for clinicians. 2012 , 12, 707-17		34
113	Methodologies used to identify and characterize interactions among antiepileptic drugs. 2012 , 5, 281-92		18
112	Detection of 22 antiepileptic drugs by ultra-performance liquid chromatography coupled with tandem mass spectrometry applicable to routine therapeutic drug monitoring. <i>Biomedical Chromatography</i> , 2012 , 26, 1519-28	1.7	65
111	Host factors affecting antiepileptic drug delivery-pharmacokinetic variability. 2012 , 64, 896-910		66
110	Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy. <i>Epilepsia</i> , 2012 , 53, e9-12	6.4	11
109	Population pharmacokinetics of lamotrigine in Indian epileptic patients. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 43-52	2.8	10

108	Application of surfactant assisted dispersive liquid-liquid microextraction as an efficient sample treatment technique for preconcentration and trace detection of zonisamide and carbamazepine in urine and plasma samples. 2013 , 1308, 25-31		68
107	Effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on the protective action of various antiepileptic drugs in the maximal electroshock-induced seizure model: a type II isobolographic analysis. 2013 , 120, 1651-63		3
106	Antiepileptic Drug Interactions. 2013 ,		23
105	Proposal of estimation method for drug concentration in blood by Raman spectroscopy of tear fluids. 2013 ,		
104	Neuroprotective effects of the mood stabilizer lamotrigine against glutamate excitotoxicity: roles of chromatin remodelling and Bcl-2 induction. 2013 , 16, 607-20		28
103	Topiramate is likely to act outside of the trigeminocervical complex. 2013 , 33, 291-300		13
102	Therapeutic drug monitoring of antiepileptic drugs by use of saliva. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 4-29	3.2	126
101	Factors influencing serum topiramate concentrations in routine therapeutic drug monitoring in Korean adult patients with epilepsy. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 177-82	3.2	8
100	Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy. 2013 , 51, 780-6		
99	^#.^t21: TLC of Psychostimulants. 2013 , 428-465		
98	HPTLC/HPLC and gravimetric methodology for the identification and quantification of gymnemic acid from <i>Gymnema sylvestrem</i> methanolic extracts. 2013 , 25, 339-361		1
97	Analysis of the long-term actions of gabapentin and pregabalin in dorsal root ganglia and substantia gelatinosa. 2014 , 112, 2398-412		29
96	Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 494-8	3.2	29
95	Therapeutic drug monitoring of levetiracetam: comparison of a novel immunoassay with an HPLC method. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 681-5	3.2	8
94	No impact of neuropathy on pharmacokinetic of lamotrigine in rat model. 2014 , 5, 15		2
93	Feasibility study of paper-based surface enhanced Raman spectroscopy of tear fluids for onsite therapeutic drug monitoring. 2014 ,		1
92	Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations. 2014 , 28, 69-77		17
91	Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach. <i>European Journal of Clinical Pharmacology</i> , 2014 , 70, 179-85	2.8	16

90	Pregabalin activates ROMK1 channels via cAMP-dependent protein kinase and protein kinase C. 2014 , 740, 35-44		4
89	Simultaneous analysis of 22 antiepileptic drugs in postmortem blood, serum and plasma using LC-MS-MS with a focus on their role in forensic cases. 2014 , 38, 485-94		55
88	Advances in anti-epileptic drug testing. 2014 , 436, 224-36		42
87	Efficacy and safety of felbamate in children with refractory epilepsy. 2014 , 18, 658-62		12
86	Antiepileptika-Therapie bei Einschränkung der Nierenfunktion. 2015 , 42, 86-92		2
85	Pharmacokinetic Optimization of Therapy. 2015 , 124-138		
84	Quantifying the Effectiveness of Dose Individualization by Simulation for a Drug With Moderate Pharmacokinetic Variability. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 641-8	3-2	7
83	Use of Antiepileptic Drugs in Patients with Chronic Kidney Disease and End Stage Renal Disease. 2015 , 28, 404-12		16
82	Monitoraggio terapeutico del levetiracetam (Keppra®): confronto tra un nuovo metodo immunologico e il metodo di riferimento in cromatografia liquida ad alta prestazione. 2015 , 4,		
81	On the Slow Diffusion of Point-of-Care Systems in Therapeutic Drug Monitoring. 2015 , 3, 20		21
80	Noninvasive sampling of gabapentin by reverse iontophoresis. 2015 , 32, 1417-24		4
79	Valproic acid exposure leads to upregulation and increased promoter histone acetylation of sepiapterin reductase in a serotonergic cell line. <i>Neuropharmacology</i> , 2015 , 99, 79-88	5-5	17
78	The role of nicotinic acetylcholine receptors in autosomal dominant nocturnal frontal lobe epilepsy. <i>Frontiers in Physiology</i> , 2015 , 6, 22	4.6	61
77	Evaluation of the Effects of Ketoconazole and Voriconazole on the Pharmacokinetics of Oxcarbazepine and Its Main Metabolite MHD in Rats by UPLC-MS-MS. 2016 , 54, 334-42		2
76	Therapeutic Drug Monitoring of Newer Antiepileptic Drugs. 2016 , 101-134		4
75	Inpatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens. 2016 , 122, 79-83		22
74	Sensitive inexpensive HPLC determination of four antiepileptic drugs in human plasma: application to PK studies. 2016 , 8, 2219-2234		14
73	An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. 2016 , 16, 303-316		93

72	Saliva and Plasma Monohydroxycarbamazepine Concentrations in Pediatric Patients With Epilepsy. <i>Therapeutic Drug Monitoring</i> , 2016 , 38, 365-70	3.2	9
71	Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016 , 41, 345-51	2.7	6
70	Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 555-62	2.8	12
69	Variation in dose and plasma level of lamotrigine in patients discharged from a mental health trust. <i>Therapeutic Advances in Psychopharmacology</i> , 2017 , 7, 17-24	4.9	8
68	Comparison of Plasma, Saliva, and Hair Levetiracetam Concentrations. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 263-268	3.2	8
67	A simple and cost-effective HPLC-UV method for the detection of levetiracetam in plasma/serum of patients with epilepsy. <i>Biomedical Chromatography</i> , 2017 , 31, e3969	1.7	7
66	Unexpected Efficacy of a Novel Sodium Channel Modulator in Dravet Syndrome. <i>Scientific Reports</i> , 2017 , 7, 1682	4.9	48
65	Treatment of Gabapentin Toxicity With Peritoneal Dialysis: Assessment of Gabapentin Clearance. <i>American Journal of Kidney Diseases</i> , 2017 , 70, 878-880	7.4	3
64	Highly Modular Bioluminescent Sensors for Small Molecules and Proteins. <i>Methods in Enzymology</i> , 2017 , 589, 365-382	1.7	4
63	Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers. <i>Frontiers in Neurology</i> , 2017 , 8, 301	4.1	184
62	Etiology and Pharmacology of Neuropathic Pain. <i>Pharmacological Reviews</i> , 2018 , 70, 315-347	22.5	155
61	Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 583-591	2.8	11
60	Population pharmacokinetics of levetiracetam in neonates with seizures. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018 , 43, 422-429	2.2	5
59	The anti-epileptic drug lamotrigine inhibits the CYP17A1 lyase reaction in vitro. <i>Biology of Reproduction</i> , 2018 , 99, 888-897	3.9	2
58	Effect of antiepileptic drug comedication on lamotrigine concentrations. <i>Croatian Medical Journal</i> , 2018 , 59, 13-19	1.6	5
57	Laser Synthesized Nanoparticles for Therapeutic Drug Monitoring. <i>Springer Series in Materials Science</i> , 2018 , 339-360	0.9	1
56	Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 526-548	3.2	167
55	Hyperpolarization-Activated Cyclic Nucleotide-Gated Non-selective (HCN) Ion Channels Regulate Human and Murine Urinary Bladder Contractility. <i>Frontiers in Physiology</i> , 2018 , 9, 753	4.6	7

54	Comparison of plasma, saliva, and hair lamotrigine concentrations. <i>Clinical Biochemistry</i> , 2019 , 74, 24-30	3.5	7
53	Integrated Microfluidic Devices Fabricated in Poly (Methyl Methacrylate) (PMMA) for On-site Therapeutic Drug Monitoring of Aminoglycosides in Whole Blood. <i>Biosensors</i> , 2019 , 9,	5.9	9
52	Glomerular Filtration Rate Is a Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese Epileptic Patients: A Population Pharmacokinetic Analysis. <i>Therapeutic Drug Monitoring</i> , 2019 , 41, 665-673	3.2	2
51	Pharmacogenetics-based population pharmacokinetic analysis of gabapentin in patients with chronic pain: Effect of OCT2 and OCTN1 gene polymorphisms. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019 , 124, 266-272	3.1	8
50	Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 381-392	2.8	7
49	A Physiologically Based Pharmacokinetic Model for Optimally Profiling Lamotrigine Disposition and Drug-Drug Interactions. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019 , 44, 389-408	2.7	7
48	The anticonvulsant lamotrigine enhances I in layer 2/3 neocortical pyramidal neurons of patients with pharmaco-resistant epilepsy. <i>Neuropharmacology</i> , 2019 , 144, 58-69	5.5	9
47	Therapeutic Drug Monitoring of Newer Antiepileptic Drugs: A Randomized Trial for Dosage Adjustment. <i>Annals of Neurology</i> , 2020 , 87, 22-29	9.4	13
46	What Are the Predictors for Achieving Therapeutic Levetiracetam Serum Concentrations in Adult Neurological Patients?. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 626-630	3.2	3
45	A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs-From phenobarbital to cenobamate and beyond. <i>Epilepsia</i> , 2020 , 61, 1543-1552	6.4	10
44	Dosing Recommendations Based on Population Pharmacokinetics of Lamotrigine in Mexican Adult Patients With Epilepsy. <i>Journal of Pharmaceutical Sciences</i> , 2020 , 109, 2902-2908	3.9	1
43	Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy. <i>Journal of Pharmaceutical Sciences</i> , 2020 , 109, 2070-2078	3.9	5
42	Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 227-238	5.5	18
41	Clinical utility of therapeutic drug monitoring of antiepileptic drugs: Systematic review. <i>Neurology: Clinical Practice</i> , 2020 , 10, 344-355	1.7	4
40	Therapeutic monitoring of antiepileptic drugs. <i>Handbook of Analytical Separations</i> , 2020 , 7, 225-256	0.7	1
39	Dosing Recommendations for Lamotrigine in Children: Evaluation Based on Previous and New Population Pharmacokinetic Models. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 677-687	2.9	1
38	Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 655-664	6.2	6
37	Population Pharmacokinetics of Levetiracetam: A Systematic Review. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 305-318	6.2	4

36	Seizures and Epilepsy in Dementia: Diagnosis and Management. 2021 , 251-290		
35	Comparison of HPLC-DAD and UPLC-MS/MS in monitoring serum concentration of lamotrigine. <i>Current Pharmaceutical Analysis</i> , 2021 , 17,	0.6	
34	Pharmacokinetics of zonisamide after oral single dosing and multiple-dose escalation administration in domestic chickens (<i>Gallus gallus</i>). <i>Veterinary Medicine and Science</i> , 2021 , 7, 1928-1937	2.1	1
33	A new rapid titration protocol for lamotrigine that reduces the risk of skin rash. <i>Epilepsia Open</i> , 2021 , 6, 394-401	4	1
32	Predictive Performance of Population Pharmacokinetic Models of Levetiracetam in Children and Evaluation of Dosing Regimen. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 1366-1375	2.9	
31	Use of extended-release and immediate-release anti-seizure medications with a long half-life to improve adherence in epilepsy: A guide for clinicians. <i>Epilepsy and Behavior</i> , 2021 , 120, 107993	3.2	5
30	Was it necessary to change the therapeutic range of topiramate?. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	0
29	Simultaneous Quantitation of Lamotrigine, Levetiracetam, 10-Hydroxycarbazepine, Topiramate, and Zonisamide in Serum Using HPLC-MS/MS. <i>Methods in Molecular Biology</i> , 2016 , 1383, 29-37	1.4	9
28	Principles of therapy in the epilepsies. 2010 , 173-235		5
27	Antiepileptic drugs. 2020 , 99-158		2
26	Therapeutic Drugs and Their Management. 2012 , 1057-1108		2
25	Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration. <i>American Journal of Case Reports</i> , 2017 , 18, 458-462	1.3	7
24	Simultaneous Determination of Carbamazepine and Carbamazepine-10,11-epoxide in Different Biological Matrices by LC-MS/MS. <i>Journal of Interdisciplinary Medicine</i> , 2017 , 2, 211-218	0.2	2
23	Determination of Two Antiepileptic Drugs in Urine by Homogenous Liquid-Liquid Extraction Performed in A Narrow Tube Combined with Dispersive Liquid-liquid Microextraction Followed by Gas Chromatography-flame Ionization Detection. <i>Iranian Journal of Pharmaceutical Research</i> , 2019 , 18, 626-636	1.1	3
22	Plasma level monitoring of psychotropics and anticonvulsants. 2009 , 1-8		1
21	Neuronal nicotinic receptors in sleep-related epilepsy: studies in integrative biology. 2012 , 2012, 262941		5
20	Population Pharmacokinetics of Levetiracetam and Dosing Evaluation in Critically Ill Patients with Normal or Augmented Renal Function. <i>Pharmaceutics</i> , 2021 , 13,	6.4	1
19	The Role of Antiepileptic Drugs in Long-Term Treatment of Bipolar Disorder. <i>Medical Psychiatry</i> , 2008 , 139-154		

18	Selected psychiatric medication-associated syndromes and emergencies. 2008 , 105-128		
17	Eficacia y seguridad de oxcarbacepina en los trastornos del Bimo: estudio naturalista que analizó el interés de las dosis plasmáticas. <i>European Psychiatry (Ed Española)</i> , 2008 , 15, 407-410		
16	Chapter 28. Seizure Disorders. 2015 ,		
15	Gabapentin. 479-488		
14	Second Generation Anticonvulsants: Gabapentin, Lamotrigene, Leveticetam, and Topiramate. 2016 , 1-18		
13	Second Generation Anticonvulsants: Gabapentin, Lamotrigine, Levetiracetam, and Topiramate. 2017 , 1065-1081		
12	Second Generation Anticonvulsants: Gabapentin, Lamotrigine, Levetiracetam, and Topiramate. 2017 , 1-18		
11	Closed-loop Neuropharmacology for Epilepsy: Distant Dream or Future Reality?. <i>Current Neuropharmacology</i> , 2019 , 17, 447-458	7.6	○
10	Antiepileptika. 2006 , 103-176		
9	Introduction. 2022 , 7-30		
8	WHAT IS THE THERAPEUTIC REFERENCE RANGE FOR LEVETIRACETAM?. <i>Therapeutic Drug Monitoring</i> , 2022 ,	3.2	
7	Significant predictors for topiramate pharmacokinetics: a systematic review of population pharmacokinetic studies. <i>Journal of Pharmacy Practice and Research</i> ,	0.7	○
6	Evaluating Therapeutic Equivalence of Generic and Original Levetiracetam in Patients with Epilepsy: A Retrospective Study.. <i>Neurology International</i> , 2022 , 14, 271-283	1.2	
5	Pharmacokinetics. 833-864		
4	Microporous Affinity Membranes and Their Incorporation into Microfluidic Devices for Monitoring of Therapeutic Antibodies. <i>SSRN Electronic Journal</i> ,	1	
3	Preparation of Molecular Imprinted Polymer Based on Chitosan as the Selective Sorbent for Solid-Phase Microextraction of Phenobarbital. <i>Journal of Analytical Methods in Chemistry</i> , 2022 , 2022, 1-9	2	1
2	Microporous affinity membranes and their incorporation into microfluidic devices for monitoring of therapeutic antibodies. 2023 , 252, 123842		
1	Simulations of topiramate dosage recommendations for poor compliance events.		○

